NmCV-5

BIOLOGICAL3 trials

Sponsors

Serum Institute of India Pvt. Ltd., Emory University

Conditions

MeningitisMeningococcal MeningitisVaccine for Meningococcal Disease

Phase 2

Study to Evaluate the Lot to Lot Consistency of SIIPL Meningococcal ACYWX Conjugate Vaccine and to Compare Its Safety and Immunogenicity With That of Licensed Meningococcal ACWY Vaccine Menactra® in Healthy Individuals 18-85 Years of Age

CompletedNCT04358731

Serum Institute of India Pvt. Ltd.Vaccine for Meningococcal Disease

Start: 2019-12-27End: 2021-03-24Updated: 2021-09-08

Phase 3

Study to Assess Immunegnicity & Safety of Pentavalent Meningococcal Vaccine (NmCV-5)

CompletedNCT03964012

Serum Institute of India Pvt. Ltd.Meningococcal Meningitis

Start: 2019-08-20End: 2021-03-04Updated: 2021-07-27

Meningococcal Serogroup ACYWX Conjugate Vaccine in Comparison With MenACWY-TT Conjugate Vaccine

CompletedNCT05093829

Emory UniversityMeningitis

Start: 2022-03-24End: 2025-02-20Updated: 2026-03-31

Related Papers

Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine targeting serogroups A, C, W, Y, and X when co-administered with routine childhood vaccines at ages 9 months and 15 months in Mali: a single-centre, double-blind, randomised, controlled, phase 3, non-inferiority trial.

2025-03-114 citations

Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine versus a quadrivalent meningococcal conjugate vaccine in adults in India: an observer-blind, randomised, active-controlled, phase 2/3 study.

2024-11-063 citations

Meningococcal ACWYX Conjugate Vaccine in 2-to-29-Year-Olds in Mali and Gambia

New England Journal of Medicine2023-05-2437 citations